Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results
October 30, 2024 16:15 ET
|
Processa Pharmaceuticals, Inc.
First patient dosed in Phase 2 clinical trial with NGC-Cap for metastatic breast cancer Positive data from preclinical studies support NGC-Iri’s ability to deliver more SN-38 to tumors compared with...
Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer
October 02, 2024 16:05 ET
|
Processa Pharmaceuticals, Inc.
Phase 2 trial is an adaptive designed randomized study comparing NGC-Cap to monotherapy capecitabineResults from this Phase 2 trial will evaluate NGC-Cap’s safety-efficacy profile and help to define...
Processa Pharmaceuticals Provides Product Pipeline and Financial Update
August 28, 2024 08:00 ET
|
Processa Pharmaceuticals, Inc.
Phase 2 trial with NGC-Cap in breast cancer underway NGC-Cap Phase 1b trial demonstrated a favorable safety profile with preliminary anti-tumor activity Preclinical studies demonstrated NGC-Iri...
Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri
August 19, 2024 08:00 ET
|
Processa Pharmaceuticals, Inc.
Delivers more cancer-killing SN-38 molecules to tumor than irinotecan and Onivyde® Studies support potential benefit as an improved treatment with fewer side effects HANOVER, Md., Aug. 19, 2024 ...
Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer
June 11, 2024 08:20 ET
|
Processa Pharmaceuticals, Inc.
Eight of 12 evaluable patients (66.7%) had progression-free survival (PFS) ranging from 5 to 11 months At the highest NGC-Cap dose, all three evaluable patients had PFS with two partial responses...
Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference
May 06, 2024 08:00 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial
April 11, 2024 08:00 ET
|
Processa Pharmaceuticals, Inc.
NGC-Cap demonstrated greater 5-FU exposure than monotherapy capecitabine at a significantly lower dose with a favorable clinical safety profile NGC-Cap holds potential for improved efficacy in more...
Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting
March 25, 2024 08:15 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, March 25, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference
February 14, 2024 13:00 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering
February 01, 2024 16:22 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...